Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAJED A KOLEILAT

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1922175694
CMS profile
178334
Location
EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$6,074.19

136 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAJED A KOLEILAT

NPI 1922175694 · CMS profile ID 178334

Allopathic & Osteopathic Physicians / Allergy & Immunology

EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922175694?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922175694?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922175694?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1922175694?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

136 matching records · $6,074.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 136 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 136.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharming Healthcare, Inc. $15.6908/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907876783 CMS
Grifols USA, LLC $18.6508/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918700508 CMS
BioCryst US Sales Co., LLC $20.2108/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946874915 CMS
GENZYME CORPORATION $25.4208/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938910369 CMS
AstraZeneca Pharmaceuticals LP $14.3008/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915084099 CMS
PFIZER INC. $12.0208/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949613409 CMS
LEO Pharma Inc. $22.0608/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936239929 CMS
GENZYME CORPORATION $5.0508/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938910399 CMS
Horizon Therapeutics plc $22.7208/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937645809 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.1808/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955688359 CMS
GlaxoSmithKline, LLC. $16.4108/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834549 CMS
ADMA BioManufacturing LLC $25.2207/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933558837 CMS
Regeneron Healthcare Solutions, Inc. $25.7007/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927240133 CMS
Amgen Inc. $11.8207/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939213851 CMS
GlaxoSmithKline, LLC. $5.2207/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834591 CMS
GENZYME CORPORATION $27.0607/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938910397 CMS
CSL Behring $20.1707/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940906867 CMS
AstraZeneca Pharmaceuticals LP $16.9607/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915431463 CMS
AstraZeneca Pharmaceuticals LP $950.0007/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914971741 CMS
Grifols USA, LLC $12.7907/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918692409 CMS
CSL Behring $20.7207/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940906863 CMS
BioCryst US Sales Co., LLC $12.9507/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946874971 CMS
GlaxoSmithKline, LLC. $13.3306/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834565 CMS
GENZYME CORPORATION $22.1606/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938910355 CMS
Amgen Inc. $10.1506/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939213849 CMS
GENZYME CORPORATION $27.9006/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938910357 CMS
GlaxoSmithKline, LLC. $10.6006/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834569 CMS
AstraZeneca Pharmaceuticals LP $15.6706/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914811831 CMS
GlaxoSmithKline, LLC. $13.8606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834587 CMS
Pharming Healthcare, Inc. $18.3406/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907876779 CMS
GENZYME CORPORATION $8.9006/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938910353 CMS
GlaxoSmithKline, LLC. $90.0005/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834583 CMS
Covis Pharma GmBH $15.1105/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953398187 CMS
OptiNose US, Inc. $21.2505/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928157325 CMS
Regeneron Healthcare Solutions, Inc. $17.0805/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927240129 CMS
GlaxoSmithKline, LLC. $15.1805/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834589 CMS
AstraZeneca Pharmaceuticals LP $950.0005/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914635593 CMS
CSL Behring $19.0704/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940906859 CMS
Covis Pharma GmBH $12.8304/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953398199 CMS
GlaxoSmithKline, LLC. $10.9904/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834573 CMS
GlaxoSmithKline, LLC. $10.0504/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944834579 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.3704/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955688355 CMS
Regeneron Healthcare Solutions, Inc. $23.3204/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927240123 CMS
Amgen Inc. $17.2704/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939213847 CMS
Grifols USA, LLC $13.4404/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918676243 CMS
PFIZER INC. $21.4504/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949087761 CMS
Aimmune Therapeutics, Inc. $13.3104/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954232231 CMS
GENZYME CORPORATION $5.3804/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938910323 CMS
AstraZeneca Pharmaceuticals LP $14.5104/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915220889 CMS
Grifols USA, LLC $10.1403/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918674303 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22,744.84 121
PY2020 $8,447.25 86
PY2021 $11,770.23 134
PY2022 $6,074.19 136
PY2023 $10,875.95 114
PY2024 $39,987.82 121
PY2025 $21,927.61 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $100,022.72 40
PY2024 Principal investigator $81,746.74 19
PY2023 Principal investigator $105,618.27 27
PY2022 Principal investigator $114,068.39 25
PY2021 Principal investigator $113,740.20 23
PY2020 Principal investigator $60,121.14 30
PY2019 Principal investigator $15,729.05 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $154.00 12/11/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048642
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 12/11/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048644
Principal investigator 1 GlaxoSmithKline, LLC. $2,400.00 11/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111062
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 11/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048640
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $428.40 10/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048638
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,958.20 10/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048636
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,130.10 10/14/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048634
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $725.60 10/09/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048632
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 09/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048630
Principal investigator 1 GlaxoSmithKline, LLC. $7,192.00 09/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118836
Principal investigator 1 GlaxoSmithKline, LLC. $749.55 09/08/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117552
Principal investigator 1 GlaxoSmithKline, LLC. $76.42 09/03/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111070
Principal investigator 1 GlaxoSmithKline, LLC. $561.00 08/21/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111034
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/21/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111040
Principal investigator 1 GlaxoSmithKline, LLC. $106.07 08/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111047
Principal investigator 1 GlaxoSmithKline, LLC. $806.00 08/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118843
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 08/19/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048603
Principal investigator 1 GlaxoSmithKline, LLC. $3,275.60 08/01/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111076
Principal investigator 1 GlaxoSmithKline, LLC. $2,062.00 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117595
Principal investigator 1 GlaxoSmithKline, LLC. $1,620.00 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117601
Principal investigator 1 GlaxoSmithKline, LLC. $9,109.88 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118824
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,130.10 07/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048628
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,650.00 07/23/2025 Non-covered Recipient Entity
DEACONESS CLINIC COMP CENTER MIDTOWN CAMPUS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549593
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.40 06/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048626
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $755.00 06/19/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048624
Principal investigator 1 GlaxoSmithKline, LLC. $2,252.45 06/16/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117589
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,537.00 06/13/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048622
Principal investigator 1 GlaxoSmithKline, LLC. $869.25 05/05/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111053
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,640.15 04/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC COMP CENTER MIDTOWN CAMPUS
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549591
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,889.50 04/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048620
Principal investigator 1 GlaxoSmithKline, LLC. $965.20 04/04/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117572
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,126.80 03/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048618
Principal investigator 1 GlaxoSmithKline, LLC. $1,092.00 03/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117577
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.40 02/27/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048615
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048672
Principal investigator 1 GlaxoSmithKline, LLC. $1,914.00 02/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117560
Principal investigator 1 GlaxoSmithKline, LLC. $915.00 02/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117583
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,112.80 01/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048613
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,327.10 01/16/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048611
Principal investigator 1 GlaxoSmithKline, LLC. $1,133.35 01/13/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117566